Table 2. Prevalence of anti-CCP+, RF+ and ANA+ and age-adjusted death rates among women who reported RA at baseline or baseline and follow-up (N=5,657).
| Anti-CCP | RF | ANA | N | Age-adjusted death rate/1000 PYs |
|---|---|---|---|---|
| - | 5042 | 13.0 (11.5-14.7) | ||
| + | 612 | 21.4 (16.0-28.5) | ||
| - | 4492 | 12.8 (11.2-14.6) | ||
| + | 1152 | 17.9 (14.4-22.4) | ||
| - | 4768 | 13.7 (12.1-15.5) | ||
| + | 881 | 14.7 (11.3-19.4) | ||
| - | - | - | 3802 | 12.5 (10.9-14.5) |
| + | - | - | 75 | 20.9 (9.9-48.3) |
| - | + | - | 487 | 14.5 (10.0-21.1) |
| - | - | + | 597 | 13.3 (9.4-18.9) |
| + | + | - | 395 | 23.3 (16.5-33.0) |
| + | - | + | 13 | 30.5 (7.9-136.8) |
| - | + | + | 142 | 19.5 (11.2-36.0) |
| + | + | + | 128 | 14.4 (6.7-31.7) |